Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 67 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Methadone placebo Clear all
Completed Early Phase 1 Interventional Results available

Galantamine and CBT4CBT Pilot to Prevent Relapse.

NCT03547622
View directory record Official record
Conditions
Methadone or Buprenorphine Detoxoxification
Interventions
MAT taper with galantamine, MAT taper with placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Stimulant Oxytocin Study

NCT03016598
View directory record Official record
Conditions
Stimulant Use & Co-occuring Opioid Use Disorders
Interventions
Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

Early Phase II Trials for Cocaine Medication Development - 1

NCT00000317
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Risperidone, Placebo, Relapse prevention counseling
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 30, 2026, 6:17 AM EDT
Withdrawn Phase 2 Interventional

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

NCT00723918
View directory record Official record
Conditions
HIV-associated Neuropathy, Polyneuropathy
Interventions
SAB378, methadone, SAB placebo, Methadone placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Diego, California • Brooklyn, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Topiramate for Cocaine Addiction

NCT00685178
View directory record Official record
Conditions
Cocaine Dependence
Interventions
topiramate, Contingency Reinforcement, placebo + NonCR
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Not applicable Interventional

Harnessing Placebo Effects in Methadone Treatment

NCT02941809
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-Related Disorders
Interventions
Open-Label Placebo (OLP)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone

NCT00218608
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders
Interventions
Disulfiram
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

NCT00061087
View directory record Official record
Conditions
ADHD, Opioid-Related Disorders, Cocaine Dependence
Interventions
Methylphenidate, Bupropion, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Directly Observed and Long-term Varenicline

NCT03365362
View directory record Official record
Conditions
Tobacco Use Disorder, Opioid-use Disorder
Interventions
Long-Term Varenicline, Short-Term Varenicline, Directly Observed Therapy, Self Administered Therapy
Drug · Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Disulfiram for Cocaine

NCT00149630
View directory record Official record
Conditions
Cocaine Dependence, Opioid Dependence
Interventions
Disulfiram, Methadone, CBT, Lactose
Drug · Behavioral · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 30, 2026, 6:17 AM EDT
Not yet recruiting Phase 3 Interventional

PO Methadone Ortho Outpatient

NCT06351215
View directory record Official record
Conditions
Arthroscopic Knee Repair, Arthroscopic Hip Repair
Interventions
Methadone group, Placebo
Drug
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol in the Treatment of Opioid Use Disorder

NCT06206291
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
Drug
Lead sponsor
Yasmin Hurd
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Not applicable Interventional Results available

The Effects of Minocycline in Opioid-maintained Patients

NCT02359006
View directory record Official record
Conditions
Opioid Dependence, Pain
Interventions
Minocycline, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance

NCT00447811
View directory record Official record
Conditions
Methadone-maintenance Subjects
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 30, 2026, 6:17 AM EDT
Terminated Phase 4 Interventional Results available

Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit

NCT02025855
View directory record Official record
Conditions
Opioid Use, Unspecified With Withdrawal, Opioid-Induced Disorders, Delirium
Interventions
Methadone, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Suvorexant for Opioid/Stimulant Co-use

NCT05546515
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Suvorexant (dual orexin receptor antagonist), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00447564
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine, placebo
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 1 Interventional

Cocaine Opioid Oxytocin Option - Limited

NCT02028533
View directory record Official record
Conditions
Opioid Use Disorder, Cocaine Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

Improving Outcomes in Neonatal Abstinence Syndrome

NCT01958476
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal
Interventions
Neonatal Morphine Solution, Methadone, Phenobarbital
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Jacksonville, Florida • Portland, Maine • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

NCT02391571
View directory record Official record
Conditions
Withdrawal Symptoms
Interventions
Oxycodone/Naltrexone Capsules, Oxycodone, Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 30, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients

NCT00577005
View directory record Official record
Conditions
Cocaine Dependence, Opioid Dependency
Interventions
levetiracetam, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 30, 2026, 6:17 AM EDT
Recruiting Phase 2 Interventional

Combined THC and CBD for OUD and Chronic Pain

NCT06544291
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder
Interventions
CBD 300mg, CBD 600mg, Placebo 0mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 30, 2026, 6:17 AM EDT
Recruiting Phase 2Phase 3 Interventional

Divided or Single Exposure (DOSE) Study

NCT05459402
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain, Methadone
Interventions
Methadone (100% dose), Methadone (50% dose)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 30, 2026, 6:17 AM EDT